Navigate Effective Endpoints, Safeguard Funding Strategy, & Translate Safe Delivery to Fast-Track from IND to Late-Clinical Trials in Rare & Common Eye Disease
Unprecedented momentum is building in 2025:
- Kriya Therapeutics are advancing through their preclinical development
- Opus Genetics and SpliceBio have entered their early trials
- Ocugen, 4D Molecular Therapeutics, and AbbVie race towards BLA approval
This surge creates an urgent demand to mitigate critical bottlenecks like endpoints, funding, delivery, and more.
The 6th Gene Therapy for Ophthalmic Disorders Summit returns in Raleigh, North Carolina, as the leading industry-specific event uniting biopharma scientists and strategists to tackle these developmental challenges head-on.
Join us to unlock the next breakthrough beyond Luxturna and accelerate your therapy to patients.
I am excited to attend the 6th Gene Therapy for Ophthalmologic Disorders Summit to engage with leading experts, gain fresh insights into advancing genetic therapies for vision loss, and explore the latest clinical and regulatory developments shaping the future of ophthalmic care.
Chief Executive Officer, Axovia Therapeutics
Explore the Full Event Program
- 6+ Hours of High-Yield Networking with Industry Leaders & Specialized Vendors
- 18 Senior Ophthalmic Gene Therapy Experts Delivering End-to-End Development Expertise
- 50:50 Split Content Focus on Prevalent & Rare Diseases Across 3 Days
Our Visionary Speaker Faculty Includes:
Who You Can Grab a Coffee With:
